EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH)
ISSN: 2992-4081 ©EEJPH Publications
Volume 5 Issue 2 2024

The Impact of AI on Drug Discovery and Development

Namukasa Mugerwa F.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

The integration of artificial intelligence (AI) into drug discovery and development is revolutionizing the pharmaceutical industry by improving efficiency, reducing costs, and accelerating timelines. AI has the potential to transform traditional processes such as target identification, virtual screening, and clinical trial design. By leveraging machine learning, deep learning, and natural language processing, AI can analyze vast amounts of biological and chemical data, predicting molecular interactions and optimizing compound design. This review examines the current and future applications of AI in drug development, highlights the challenges associated with its adoption, and examines the transformative role AI is poised to play in enhancing precision medicine and personalized therapies. Despite advancements, AI's full potential in drug discovery is yet to be realized due to technical, ethical, and regulatory challenges.

Keywords: Artificial intelligence (AI), Drug discovery, Machine learning (ML), Deep learning (DL), Drug development.

INTRODUCTION

Since the 1980s, the pharmaceutical industry has time and again been identified as an area with untapped potential for technology transfer. Technological developments, specifically those made in the area of artificial intelligence, are anticipated to transform processes in drug discovery and development. AI can be used to analyze existing regulatory filing data and develop structural analogs to previously developed drugs. This application demonstrates how existing regulatory filing data can be used to expedite de-risked drugs through preclinical development while developing approval pathways for commencing clinical trials [1, 2]. For AI technologies, the primary directive that drives investments made by biopharmaceutical companies is efficiency. Drug discovery and development is one of the most necessary and innovative areas of drug development pathways for the treatment of disease. Historically, drug discovery has started with a hypothesis-driven activity and transitioned into preclinical and clinical activities before regulatory submission. Yet this investigative approach and commercialization development cycle yields an estimated success rate for Phase I clinical trials of 63.2%. The development of a single drug to treat human disease is estimated to require $1.395 billion in R&D and 14.2 years. Progress in AI technologies allows the potential to change these processes, generating significant efficiencies. Yet, despite considering all evidence, experts can only speculate on the impact of AI on drug discovery and development and are unable to drive action for the technologies' inclusion. It is expedient for biopharmaceutical companies to be aware of commercial opportunities that may arise from the development of these technologies. Experience demonstrates that late adopters are limited in terms of competition and their learning curve [3, 4].

OVERVIEW OF DRUG DISCOVERY AND DEVELOPMENT

The discovery and development of new drugs are highly complex processes. These generally consist of several discrete steps from initial concept to development, clinical testing, and eventual licensure. The first important step in this process is the identification of a potential target, the alteration of which may result in a given disease state being modified. This step is generally performed by industry and academic laboratories using a variety of approaches. Once a suitable target has been identified, the next steps generally flow on due to the massive increase in resources, both technical and financial, that are generally required. An effective 'drug' or treatment must also pass many subsequent levels of scrutiny and testing,

including the possibility of failure at any of these steps [5, 6]. In broad terms, the steps involved in the creation of a drug or treatment that can be brought to the widest possible population are: 1) translational research to demonstrate the target is involved in disease pathophysiology and pathology; 2) proof of concept animal models to provide initial safety and biological activity data; 3) preclinical testing; 4) Phase I to confirm safety, with a typical duration of 1–2 years; 5) Phase II to demonstrate that a treatment is effective (while still monitoring long-term safety), with a typical duration of 1–3 years; 6) Phase III to confirm the effect seen in Phase II on clinically relevant endpoints, such as mortality and its quality, which is the key step, with a typical duration of 3–5 years. A particular era in the development of new drugs has seen a reduction in the identification of new drugs for a range of disease states. This 'innovation gap' is now being increasingly viewed with alarm, as the current armamentarium available for disease states such as infectious diseases, cancer, depression, diabetes, and many others is inadequate for the demands of the population. Technological advances now provide us with the ability to gather immense amounts of biological information that ultimately motivates drug development. This should shorten the drug discovery process and make it more robust by providing increased information on candidate compounds and therapeutics from the very beginning of the project [7, 8].

FUNDAMENTALS OF ARTIFICIAL INTELLIGENCE

Artificial intelligence (AI) accounts for several calculation technologies and simulates cognitive functions in the human mind. Machine learning (ML), deep learning (DL), and natural language processing (NLP) are three different types of AI devices. The ability to process and analyze raw data separates AI systems like machine learning, natural language processing, and deep learning. Some AI techniques, such as predictive modeling and data analysis, can process vast quantities of data before planning an appropriate approach. A definition of AI is offered by one individual. Artificial intelligence is an algorithm or device involving computational intelligence with a capacity to execute complex functions. Various AI technologies exist, including machine learning, natural language processing, and deep learning [9, 10]. The job of ML in the pharmaceutical environment might be to manage and treat illness. AI embodies various ethical and moral considerations related to its applications, including guidelines for drug development. Data analysis, predictive modeling, and advanced algorithms all demonstrate the potential of machine learning. That is, the data-driven method integrates information across numerous sources for drug use, repurposing, generation, and discovery of treatment targets. The DL of AI can combat various biological methods across multiple diseases. Artificial intelligence technologies assist in the location of drug objective sites. The growing success of AI may bring us closer to precision pharmacotherapy than previously considered [11, 12].

APPLICATIONS OF AI IN DRUG DISCOVERY AND DEVELOPMENT

AI can play a role in a range of research and development activities within the discovery-to-market pipeline. While the hurdles of drug development are well documented, this section aims to provide readers with an understanding of a few potential application areas in which AI could be employed to support inefficiencies in terms of research and process. AI can make it much easier to search for potential drug targets. There are a number of subfields focused on optimizing virtual screening and compound design, based on the myriad of chemical compounds to which a given protein target may be able to bind [13, 14]. It's already possible to point to specific case studies where AI engines have been employed successfully within pharmaceutical development to deliver new molecules to clinical trials or to market in a faster time than traditional approaches. The use of AI in drug discovery and development also allows researchers to handle raw data and complex interactions better. Genetic and imaging data can provide a profound level of resolution in pursuit of new reagents, biological pathways, and new indications for already marketed small molecules. However, datasets of this size are challenging to interpret manually or via traditional statistical approaches. Also, using AI to interpret this data can support the development of predictive analytics that allows lifestyle drugs, such as those for pain and weight loss, to be personalized to the specific metabolic and genetic profiles of prospective patients. Personalized medicines are going to play an increasingly important role in healthcare, considering that most people respond differently to the same block of therapy based on such metrics [15, 16].

CHALLENGES AND FUTURE DIRECTIONS

Drug discovery and development is a complex, lengthy, and expensive process, requiring the nurturing and integration of a multitude of scientific disciplines. In this review, we have presented multiple areas in which, in recent years, AI and machine learning in particular have impacted the progression of drug discovery and development and helped in accelerating the progression of novel drugs to the clinic. These areas span from early pre-clinical drug discovery stages such as virtual screening, QSAR, and de novo drug design, to large-scale phenotypic high-content screening and computer vision for discovering and characterizing drugs in complex biological contexts. Despite the recent successes, the adoption and

broader use of more sophisticated machine learning methods remain a challenge, and manual AI intervention is still necessary to make real progress. It is the expert who deploys domain knowledge in unison with the strengths of these highly modern AI approaches—this is not about AI replacing biologists but about augmenting human capabilities. In recent years, the bioinformatics field has seen a great increase in available public molecular datasets and a selection of deep learning models have been applied to tasks in drug discovery. However, besides yielding high-quality datasets, the incorporation of domain knowledge and insights generated by using biology-inspired modeling approaches and generative models could considerably improve novel drug identification tasks that require complex responses or reactions on the target, as well as early safety tests. Therefore, to harness the promise of AI and machine learning in the next decade of drug discovery research, we believe that advances beyond the field of computer science are crucial [17, 18].

CONCLUSION

AI is reshaping the landscape of drug discovery and development, providing significant improvements in efficiency, cost reduction, and speed. From early target identification to clinical trial optimization, AI offers numerous benefits that can overcome the traditional bottlenecks of drug development. While AI has already demonstrated success in various stages of the drug pipeline, its broader adoption faces challenges related to data quality, integration of biological knowledge, and regulatory approval. Moving forward, interdisciplinary collaboration between AI experts, biologists, and regulatory bodies will be essential to fully harness the transformative power of AI and ensure its seamless incorporation into the pharmaceutical industry.

REFERENCES

1. Ravi R, Janodia MD. University-industry technology transfer in India: A plausible model based on success stories from the USA, Japan, and Israel. Journal of the Knowledge Economy. 2022 Jun;13(2):1692-713.
2. Dahl CL. Did the America Invents Act Change University Technology Transfer?. Tex. Intell. Prop. LJ. 2021;29:1.
3. Gardner RA, White C, Elsallab M, Farnia S, Fraint E, Grilley B, Bateman-House A, Grupp SA, Kenderian S, Locke FL, Nikiforow S. ACT To Sustain: Adoptive Cell Therapy To Sustain access to non-commercialized genetically modified cell therapies. Transplantation and Cellular Therapy. 2024 May 16.
4. Schmitt AA. INTRODUCING THE LIFE SCIENCES INNOVATION CASE STUDY PROJECT. Berkeley Technology Law Journal. 2024 Jan 2;39.
5. Rudrapal M, Khairnar SJ, Jadhav AG. Drug repurposing (DR): an emerging approach in drug discovery. Drug repurposing-hypothesis, molecular aspects and therapeutic applications. 2020 Jul 13;10.
6. Kenakin TP. Pharmacology in drug discovery and development: Understanding drug response. Elsevier; 2024 May 21.
7. Nathan R, Monk CT, Arlinghaus R, Adam T, Alós J, Assaf M, Baktoft H, Beardsworth CE, Bertram MG, Bijleveld AI, Brodin T. Big-data approaches lead to an increased understanding of the ecology of animal movement. Science. 2022 Feb 18;375(6582):eabg1780. rug.nl
8. Raparthi M, Kasaraneni BP, Gayam SR, Kondapaka KK, Thuniki P, Putha S, Nimmagadda VS, Sahu MK, Kuna SS, Pattyam SP. Quantum Sensing Technologies for Biomedical Applications: Investigating the Advancements and Challenges. Journal of Computational Intelligence and Robotics. 2022 Mar 12;2(1):21-32. thesciencebrigade.com
9. Dai CP, Ke F. Educational applications of artificial intelligence in simulation-based learning: A systematic mapping review. Computers and Education: Artificial Intelligence. 2022 Jan 1;3:100087.
10. Cavedoni S, Chirico A, Pedroli E, Cipresso P, Riva G. Digital biomarkers for the early detection of mild cognitive impairment: artificial intelligence meets virtual reality. Frontiers in human neuroscience. 2020 Jul 24;14:245. frontiersin.org
11. Ashok M, Madan R, Joha A, Sivarajah U. Ethical framework for Artificial Intelligence and Digital technologies. International Journal of Information Management. 2022 Feb 1;62:102433. reading.ac.uk
12. Stahl BC. From computer ethics and the ethics of AI towards an ethics of digital ecosystems. AI and Ethics. 2022 Feb;2(1):65-77.
13. Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug discovery today. 2021 Feb 1;26(2):511-24.

14. Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, Garcia-Fandino R. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals. 2023 Jun 18;16(6):891. mdpi.com
15. Lou B, Wu L. AI on drugs: Can artificial intelligence accelerate drug development? Evidence from a large-scale examination of bio-pharma firms. Evidence from a Large-scale Examination of Bio-pharma Firms,(March 15, 2021). MISQ Forthcoming. 2021 Mar 15.
16. Jiang J, Ma X, Ouyang D, Williams III RO. Emerging artificial intelligence (AI) technologies used in the development of solid dosage forms. Pharmaceutics. 2022 Oct 22;14(11):2257.
17. Vatansever S, Schlessinger A, Wacker D, Kaniskan HÜ, Jin J, Zhou MM, Zhang B. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Medicinal research reviews. 2021 May;41(3):1427-73. wiley.com
18. Zhavoronkov A, Vanhaelen Q, Oprea TI. Will artificial intelligence for drug discovery impact clinical pharmacology?. Clinical Pharmacology & Therapeutics. 2020 Apr;107(4):780-5. wiley.com

CITE AS: Namukasa Mugerwa F. (2024). The Impact of AI on Drug Discovery and Development. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 5(2):25-28